On March 23, Pfizer issued a press release announcing that a new Lyme disease vaccine candidate has demonstrated “strong ...
Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non‑small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results